- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07941570
The Impact of Using a Non-motorised Physical Assistance Device on the Prevention of Musculoskeletal Disorders Amongst Care-givers (TM2S)
This experimental study uses a Single-Case Experimental Design (SCED) with multiple baselines across participants to evaluate the impact of a non motorized assistive device (DAP) on muscle effort in care givers during their professional activities. Each participant completes a 12-day protocol consisting of three phases (A1 - B - A2), with the initial baseline (A1, no device) randomized between 2 and 6 days, followed by a 6-day intervention phase (B, wearing the non-motorized DAP), and a final withdrawal phase (A2, no device) adjusted to complete the 12-day period. Muscle effort is continuously quantified as a percentage of maximum voluntary contraction using mechanomyographic sensors (MOTEN Technologies) placed on the lumbar and biceps muscles, as well as the quadriceps at the Fondation Saint-Hélier site.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Bastien Fraudet
- Numero di telefono: +33299295043
- Email: bastien.fraudet@fondationsainthelier.com
Luoghi di studio
-
-
-
Landivisiau, Francia
- Fondation Ildys - EHPAD Saint Vincent
-
Contatto:
- Manon Le Goff
- Numero di telefono: +33298028308
- Email: manon.legoff@ildys.org
-
Investigatore principale:
- Sylvia Courtes
-
Ploemeur, Francia, 56270
- Centre Mutualiste de Rééducation et de Réadaptation Fonctionnelles (CMRRF) de Kerpape
-
Contatto:
- Marie Caroline Fortuné
- Numero di telefono: +33297826023
- Email: marie-caroline.fortune@vyv3.fr
-
Investigatore principale:
- Cécile Diot
-
Rennes, Francia
- Fondation Saint Helier
-
Contatto:
- Estelle Cézé
- Numero di telefono: +33299295043
- Email: estelle.ceze@fondationsainthelier.com
-
Investigatore principale:
- Estelle Cézé
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Aged 18 years and older.
- Height between 160 cm and 200 cm.
- Professional care-giver working in SMR (Medical and Rehabilitation Care) or medico-social departments of partner healthcare facilities.
- Willing to wear the non-motorized DAP under the conditions defined by the protocol.
- Affiliated with or beneficiary of a national social security scheme.
- Having provided free and informed written consent.
Exclusion Criteria:
- Self-reported back, leg, or knee pathology that raises doubts regarding the safe use of the non-motorized DAP without prior medical clearance.
- Pregnant, parturient, or breastfeeding women.
- Persons deprived of liberty by a judicial or administrative decision (including legal guardianship, trusteeship, or court protection).
- Persons receiving psychiatric care or admitted to a healthcare or social establishment for reasons other than research.
- Persons in emergency situations unable to express prior informed consent.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Non-motorized DAP Intervention
Single group following a 12-day A1-B-A2 SCED protocol. Participants undergo a randomized baseline of 2-6 days without the device (A1), a 6-day intervention phase wearing the non-motorized DAP during work activities (B), and an adjusted withdrawal phase without the device (A2). |
Participants wear a non-motorized device for posture assistance (DAP) during their regular professional activities as nurse's aides for 6 consecutive days (Phase B of the 12-day A1-B-A2 SCED protocol). Muscle effort is continuously monitored using mechanomyographic sensors (MOTEN Technologies).
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Maximum Voluntary Contraction (% MVC) of target muscle groups
Lasso di tempo: Daily during work hours over the 12-day study protocol
|
Muscle effort is continuously quantified via mechanomyography (MMG) using MOTEN Technologies sensors. The primary outcome is the muscle effort level expressed as a percentage of the individual's maximum voluntary contraction (% MVC) for each monitored muscle group (lumbar and biceps muscles across all sites; quadriceps muscles at the Fondation Saint-Hélier site). Measures are compared across the baseline (A1), intervention (B), and withdrawal (A2) phases. |
Daily during work hours over the 12-day study protocol
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in postural strain measured by mechanomyography (MMG)
Lasso di tempo: Daily during work hours over the 12-day study protocol
|
Postural strain during daily professional activities is evaluated using mechanomyographic (MMG) sensors (MOTEN Technologies) placed on target muscle groups. Measures are compared across the baseline (A1), intervention (B), and withdrawal (A2) phases. |
Daily during work hours over the 12-day study protocol
|
|
Change in perceived effort score using a Numerical Rating Scale (NRS)
Lasso di tempo: Twice daily (after each half-day work shift) over the 12-day study protocol
|
Perceived exertion during work tasks is assessed using a 0 to 10 Numerical Rating Scale (NRS/EVN), where 0 represents very low effort and 10 represents very high effort. |
Twice daily (after each half-day work shift) over the 12-day study protocol
|
|
Change in perceived fatigue score using a Numerical Rating Scale (NRS)
Lasso di tempo: Twice daily (before and after each full work day) over the 12-day study protocol
|
Subjective physical fatigue is assessed using a 0 to 10 Numerical Rating Scale (NRS/EVN), where 0 represents very low fatigue and 10 represents very high fatigue. |
Twice daily (before and after each full work day) over the 12-day study protocol
|
|
User satisfaction score with the non-motorized DAP (ESAT questionnaire)
Lasso di tempo: At the end of Phase B (Day 6 of wearing the device)
|
User satisfaction with the assistive device will be assessed using the 8-item Device subscale of the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0 / ESAT). Items are rated on a 5-point Likert scale from 1 to 5, yielding a total sum score ranging from 8 to 40, where higher scores indicate greater satisfaction |
At the end of Phase B (Day 6 of wearing the device)
|
|
Acceptability score based on the UTAUT model
Lasso di tempo: Baseline (prior to Phase A1/B) and Post-Intervention (At the end of day 6 of phase B)
|
Technology acceptance will be assessed across the constructs of the Unified Theory of Acceptance and Use of Technology (UTAUT) questionnaire. Each item is rated on a 7-point Likert scale from 1 (strongly disagree) to 7 (strongly agree). Each item also belongs one of several subscales. Mean scores are calculated separately for each subscale, ranging from 1 to 7, where higher scores indicate greater technology acceptance. |
Baseline (prior to Phase A1/B) and Post-Intervention (At the end of day 6 of phase B)
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2026-A01360-51
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .